{"success":true,"data":{"pressRelease":{"id":"50040","rtpr_id":"nACSr1tvca","ticker":"TLSI","exchange":"NASDAQ","all_tickers":["TLSI"],"title":"Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TriSalus Life Sciences, Inc. (TLSI) and Encourages Investors to Learn More About the Investigation","author":"ACCESSWIRE","published_at":"2026-05-31T15:00:10.271Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May\n31, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential\nclaims on behalf of purchasers of TriSalus Life Sciences, Inc. (\"TriSalus\" or\n\"the Company\") (NASDAQ:TLSI). Investors who purchased TriSalus securities are\nencouraged to obtain additional information and assist the investigation by\nvisiting the firm's site: bgandg.com/TLSI.\n(https://bgandg.com/TLSI/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=TLSI)\n(https://app.accessnewswire.com/imagelibrary/fe77cba7-a20d-4166-8eee-15204ba8f034/bronstein-gewirtz-and-grossman-llc.png)\nTriSalus Investigation Details\n\nOn May 12, 2026, TriSalus reported first quarter results, including revenue of\n$8.90M, a decline of 2.92% year over year. The Company further announced a cut\nto full year revenue guidance to $54 million to $57, a cut of $5.5 million at\nthe midpoint compared to prior guidance. In the accompanying earnings call,\nmanagement explained \"the driver of this revision includes both the lower Q1\nrevenues from the commercial expansion and the delayed FDA clearance timing\nfor TriNav Advance.\" Management further stated FDA clearance for TriNav\nAdvance \"is now running approximately 5 months past the 30-day MDUFA review\ngoal.\" Following this news, the price of the Company's stock dropped.\n\nWhat's Next for TriSalus Investors?\n\nIf you are aware of any facts relating to this investigation or purchased\nTriSalus securities, you can assist this investigation by visiting the firm's\nsite: bgandg.com/TLSI\n(https://bgandg.com/TLSI/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=TLSI).\nYou can also contact Peretz Bronstein or his client relations manager, Nathan\nMiller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911 (tel:+9175900911)\n\nNo Cost to TriSalus Investors\n\nWe, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions\non a contingency fee basis. That means we will ask the court to reimburse us\nfor out-of-pocket expenses and attorneys' fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for TriSalus Securities Investigation?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide.\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1169987)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSr1tvca","title":"Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TriSalus Life Sciences, Inc. (TLSI) and Encourages Investors to Learn More About the Investigation","author":"ACCESSWIRE","ticker":"TLSI","created":"2026-05-31T15:00:10.271Z","tickers":["TLSI"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May\n31, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential\nclaims on behalf of purchasers of TriSalus Life Sciences, Inc. (\"TriSalus\" or\n\"the Company\") (NASDAQ:TLSI). Investors who purchased TriSalus securities are\nencouraged to obtain additional information and assist the investigation by\nvisiting the firm's site: bgandg.com/TLSI.\n(https://bgandg.com/TLSI/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=TLSI)\n(https://app.accessnewswire.com/imagelibrary/fe77cba7-a20d-4166-8eee-15204ba8f034/bronstein-gewirtz-and-grossman-llc.png)\nTriSalus Investigation Details\n\nOn May 12, 2026, TriSalus reported first quarter results, including revenue of\n$8.90M, a decline of 2.92% year over year. The Company further announced a cut\nto full year revenue guidance to $54 million to $57, a cut of $5.5 million at\nthe midpoint compared to prior guidance. In the accompanying earnings call,\nmanagement explained \"the driver of this revision includes both the lower Q1\nrevenues from the commercial expansion and the delayed FDA clearance timing\nfor TriNav Advance.\" Management further stated FDA clearance for TriNav\nAdvance \"is now running approximately 5 months past the 30-day MDUFA review\ngoal.\" Following this news, the price of the Company's stock dropped.\n\nWhat's Next for TriSalus Investors?\n\nIf you are aware of any facts relating to this investigation or purchased\nTriSalus securities, you can assist this investigation by visiting the firm's\nsite: bgandg.com/TLSI\n(https://bgandg.com/TLSI/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=TLSI).\nYou can also contact Peretz Bronstein or his client relations manager, Nathan\nMiller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911 (tel:+9175900911)\n\nNo Cost to TriSalus Investors\n\nWe, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions\non a contingency fee basis. That means we will ask the court to reimburse us\nfor out-of-pocket expenses and attorneys' fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for TriSalus Securities Investigation?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide.\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1169987)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-31T15:00:10.388677594Z","server_sent_at_ms":1780239610388},"received_at":"2026-05-31T15:00:10.442Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1169987"},"analysis":{"id":"39472","press_release_id":"50040","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bronstein, Gewirtz & Grossman, LLC announced an investigation into potential securities claims on behalf of TriSalus Life Sciences investors.\n\nThe firm cites TriSalus' Q1 revenue of $8.90M (down 2.92% YoY) and a $5.5M midpoint cut to full-year guidance as drivers for the inquiry.\n\nThis is a routine law-firm solicitation encouraging investors to contact the firm; it does not represent a new disclosure from the company or a court action.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"revenue":8900000,"guidance":"Full year revenue guidance cut to $54 million to $57 million, a cut of $5.5 million at the midpoint compared to prior guidance","revenueYoy":"-2.92%"},"quotedText":"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace","namedEntities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner, Bronstein, Gewirtz & Grossman, LLC"},{"name":"Nathan Miller","role":"Client Relations Manager, Bronstein, Gewirtz & Grossman, LLC"}],"products":["TriNav Advance"],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff law firm"},{"name":"TriSalus Life Sciences, Inc.","ticker":"TLSI"}],"dollarAmounts":[{"amount":"$8.90M","context":"Q1 revenue"},{"amount":"$54 million to $57 million","context":"updated full year revenue guidance"},{"amount":"$5.5 million","context":"midpoint cut in guidance"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bronstein, Gewirtz & Grossman, LLC. No new disclosure from the issuer; no certified class, no settlement. Boilerplate investigation announcement."},"tickerRelevance":{"others":[],"primary":"TLSI"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bronstein, Gewirtz & Grossman, LLC announced an investigation into potential securities claims on behalf of TriSalus Life Sciences investors.\n\nThe firm cites TriSalus' Q1 revenue of $8.90M (down 2.92% YoY) and a $5.5M midpoint cut to full-year guidance as drivers for the inquiry.\n\nThis is a routine law-firm solicitation encouraging investors to contact the firm; it does not represent a new disclosure from the company or a court action.","key_figures":{"revenue":8900000,"guidance":"Full year revenue guidance cut to $54 million to $57 million, a cut of $5.5 million at the midpoint compared to prior guidance","revenueYoy":"-2.92%"},"named_entities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner, Bronstein, Gewirtz & Grossman, LLC"},{"name":"Nathan Miller","role":"Client Relations Manager, Bronstein, Gewirtz & Grossman, LLC"}],"products":["TriNav Advance"],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff law firm"},{"name":"TriSalus Life Sciences, Inc.","ticker":"TLSI"}],"dollarAmounts":[{"amount":"$8.90M","context":"Q1 revenue"},{"amount":"$54 million to $57 million","context":"updated full year revenue guidance"},{"amount":"$5.5 million","context":"midpoint cut in guidance"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-31T15:05:43.238Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":24379,"modelName":"george-droid-qwen-72b"}}